Analysis of the clinical efficiency of eradication therapy in patients with coronary heart disease associated with gastroduodenal pathology

• Published in: Terapevtic̆eskii arhiv Vol. 89; no. 8; pp. 37 - 42
• Main Authors: Simonova, Zh G, Martusevich, A K, Tarlovskaya, E I
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) "Consilium Medicum" Publishing house 01.01.2017
• Subjects: Aged; Antacids - therapeutic use; Anti-Bacterial Agents - therapeutic use; Comorbidity; Coronary Disease - diagnosis; Coronary Disease - epidemiology; Coronary Disease - physiopathology; coronary heart disease; Drug Monitoring - methods; Drug Therapy, Combination - methods; eradication therapy; Female; gastroduodenal pathology; Gastrointestinal Tract - microbiology; Helicobacter Infections - diagnosis; Helicobacter Infections - drug therapy; Helicobacter Infections - epidemiology; Helicobacter Infections - psychology; Helicobacter pylori - drug effects; Helicobacter pylori - isolation & purification; Humans; Male; Middle Aged; Outcome and Process Assessment (Health Care); Proton Pump Inhibitors - therapeutic use; Quality of Life; Russia - epidemiology; gastroduodenal pathology; eradication therapy; coronary heart disease
• ISSN: 0040-3660; 2309-5342
• DOI: 10.17116/terarkh201789837-42

To comparatively analyze the clinical efficiency of eradiation therapy (ET) in patients with coronary heart disease (CHD) concurrent with gastroduodenal pathology (GDP). The study was conducted in three steps. In Step 1, 1588 patients with chronic CHD were examined. In Step 2, the characteristics of the course of CHD concurrent with Helicobacter pylori-associated GDP in 147 patients with these conditions compared to the same number of CHD patients without GDP. In Step 3, the impact of a GDP treatment option on the efficiency of treatment was investigated in the patients with CHD. Group 1 received ET + basic therapy (BT); Group 2 used antisecretory therapy + BT; Group 3 consisted of CHD patients without concomitant GDP who received BT only. The time course of changes in clinical and quality-of-life (QOL) indicators was assessed. The patients with CHD concurrent with GDP have a more severe course of the disease as manifested by deterioration in clinical status and QOL. After ET, anginal attack rates were decreased by 62.6% in Group 1, by 30.7% in Group 2 (during antisecretory therapy), and by 29.5% in Group 3. The level of physical QOL increased by 23.7% in Group 1, which was not observed in Groups 2 and 3. Inclusion of ET in an algorithm for treating CHD patients with GDP promotes the angina stability and normalizes QOL in the patients.